Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer

Background:Epidermal growth factor receptor-mutated (EGFR+) non-small-cell lung cancer (NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted therapies, but implementation is challenging.Methods:EGFR+ NSCLC patients treated with first/second-generation (1G/2G)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Magios, Nikolaus (VerfasserIn) , Bozorgmehr, Farastuk (VerfasserIn) , Volckmar, Anna-Lena (VerfasserIn) , Kazdal, Daniel (VerfasserIn) , Kirchner, Martina (VerfasserIn) , Herth, Felix (VerfasserIn) , Heußel, Claus Peter (VerfasserIn) , Eichhorn, Florian (VerfasserIn) , Meister, Michael (VerfasserIn) , Muley, Thomas (VerfasserIn) , El-Shafie, Rami (VerfasserIn) , Fischer, Jürgen (VerfasserIn) , Faehling, Martin (VerfasserIn) , Kriegsmann, Mark (VerfasserIn) , Schirmacher, Peter (VerfasserIn) , Bischoff, Helge (VerfasserIn) , Stenzinger, Albrecht (VerfasserIn) , Thomas, Michael (VerfasserIn) , Christopoulos, Petros (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: March 24, 2021
In: Therapeutic advances in medical oncology
Year: 2021, Jahrgang: 13, Pages: 1-13
ISSN:1758-8359
DOI:10.1177/1758835921996509
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1177/1758835921996509
Volltext
Verfasserangaben:Nikolaus Magios, Farastuk Bozorgmehr, Anna-Lena Volckmar, Daniel Kazdal, Martina Kirchner, Felix J. Herth, Claus-Peter Heussel, Florian Eichhorn, Michael Meister, Thomas Muley, Rami A. Elshafie, Jürgen R. Fischer, Martin Faehling, Mark Kriegsmann, Peter Schirmacher, Helge Bischoff, Albrecht Stenzinger, Michael Thomas and Petros Christopoulos

MARC

LEADER 00000caa a2200000 c 4500
001 1760352888
003 DE-627
005 20230428014400.0
007 cr uuu---uuuuu
008 210612s2021 xx |||||o 00| ||eng c
024 7 |a 10.1177/1758835921996509  |2 doi 
035 |a (DE-627)1760352888 
035 |a (DE-599)KXP1760352888 
035 |a (OCoLC)1341416210 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
084 |a 33  |2 sdnb 
100 1 |a Magios, Nikolaus  |e VerfasserIn  |0 (DE-588)1163245836  |0 (DE-627)1027456774  |0 (DE-576)507848578  |4 aut 
245 1 0 |a Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer  |c Nikolaus Magios, Farastuk Bozorgmehr, Anna-Lena Volckmar, Daniel Kazdal, Martina Kirchner, Felix J. Herth, Claus-Peter Heussel, Florian Eichhorn, Michael Meister, Thomas Muley, Rami A. Elshafie, Jürgen R. Fischer, Martin Faehling, Mark Kriegsmann, Peter Schirmacher, Helge Bischoff, Albrecht Stenzinger, Michael Thomas and Petros Christopoulos 
264 1 |c March 24, 2021 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 12.06.2021 
520 |a Background:Epidermal growth factor receptor-mutated (EGFR+) non-small-cell lung cancer (NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted therapies, but implementation is challenging.Methods:EGFR+ NSCLC patients treated with first/second-generation (1G/2G) TKI at our institution with a last follow-up after osimertinib approval (February 2016), were analyzed retrospectively, and the results compared with published data under osimertinib.Results:A total of 207 patients received erlotinib (37%), gefitinib (16%) or afatinib (47%). The median age was 66?years, with a predominance of female (70%), never/light-smokers (69%). T790M testing was performed in 174/202 progressive cases (86%), positive in 93/174 (53%), and followed by osimertinib in 87/93 (94%). Among the 135 deceased patients, 94 (70%) received subsequent systemic treatment (43% chemotherapy, 39% osimertinib), while 30% died without, either before (4%) or after progression, due to rapid clinical deterioration (22%), patient refusal of further therapy (2%), or severe competing illness (2%). Lack of subsequent treatment was significantly (4.5x, p? 
650 4 |a EGFR T790M mutation 
650 4 |a EGFR+ NSCLC 
650 4 |a overall survival 
650 4 |a rebiopsy 
650 4 |a second line 
650 4 |a tyrosine kinase inhibitor 
700 1 |a Bozorgmehr, Farastuk  |d 1979-  |e VerfasserIn  |0 (DE-588)141921811  |0 (DE-627)632526734  |0 (DE-576)326848150  |4 aut 
700 1 |a Volckmar, Anna-Lena  |d 1984-  |e VerfasserIn  |0 (DE-588)173874916  |0 (DE-627)698776666  |0 (DE-576)134713478  |4 aut 
700 1 |a Kazdal, Daniel  |d 1983-  |e VerfasserIn  |0 (DE-588)114929650X  |0 (DE-627)1009614088  |0 (DE-576)496635867  |4 aut 
700 1 |a Kirchner, Martina  |d 1973-  |e VerfasserIn  |0 (DE-588)1017178976  |0 (DE-627)676266363  |0 (DE-576)353239747  |4 aut 
700 1 |a Herth, Felix  |e VerfasserIn  |0 (DE-588)1016095236  |0 (DE-627)705477568  |0 (DE-576)351509925  |4 aut 
700 1 |a Heußel, Claus Peter  |e VerfasserIn  |0 (DE-588)1048631389  |0 (DE-627)780769422  |0 (DE-576)40288146X  |4 aut 
700 1 |a Eichhorn, Florian  |d 1984-  |e VerfasserIn  |0 (DE-588)143005952  |0 (DE-627)641429045  |0 (DE-576)334573483  |4 aut 
700 1 |a Meister, Michael  |e VerfasserIn  |0 (DE-588)1078792046  |0 (DE-627)839461402  |0 (DE-576)451890108  |4 aut 
700 1 |a Muley, Thomas  |e VerfasserIn  |0 (DE-588)1056885432  |0 (DE-627)794179169  |0 (DE-576)16759284X  |4 aut 
700 1 |a El-Shafie, Rami  |d 1989-  |e VerfasserIn  |0 (DE-588)110057378X  |0 (DE-627)859521427  |0 (DE-576)469743859  |4 aut 
700 1 |a Fischer, Jürgen  |d 1953-  |e VerfasserIn  |0 (DE-588)133724484  |0 (DE-627)691747725  |0 (DE-576)300052510  |4 aut 
700 1 |a Faehling, Martin  |d 1966-  |e VerfasserIn  |0 (DE-588)1171164823  |0 (DE-627)1040402135  |0 (DE-576)513619356  |4 aut 
700 1 |a Kriegsmann, Mark  |d 1987-  |e VerfasserIn  |0 (DE-588)103740324X  |0 (DE-627)755668782  |0 (DE-576)39141870X  |4 aut 
700 1 |a Schirmacher, Peter  |d 1961-  |e VerfasserIn  |0 (DE-588)1020440112  |0 (DE-627)691221197  |0 (DE-576)360427448  |4 aut 
700 1 |a Bischoff, Helge  |d 1958-  |e VerfasserIn  |0 (DE-588)111184576  |0 (DE-627)389658286  |0 (DE-576)167287249  |4 aut 
700 1 |a Stenzinger, Albrecht  |e VerfasserIn  |0 (DE-588)139606106  |0 (DE-627)703395238  |0 (DE-576)312432755  |4 aut 
700 1 |a Thomas, Michael  |e VerfasserIn  |0 (DE-588)1054438781  |0 (DE-627)79152213X  |0 (DE-576)41027089X  |4 aut 
700 1 |a Christopoulos, Petros  |d 1977-  |e VerfasserIn  |0 (DE-588)138659702  |0 (DE-627)604886756  |0 (DE-576)308488067  |4 aut 
773 0 8 |i Enthalten in  |t Therapeutic advances in medical oncology  |d Thousand Oaks, Calif. : Sage, 2009  |g 13(2021) vom: Jan., Artikel-ID 1758835921996509, Seite 1-13  |h Online-Ressource  |w (DE-627)604082282  |w (DE-600)2503443-1  |w (DE-576)308904494  |x 1758-8359  |7 nnas  |a Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer 
773 1 8 |g volume:13  |g year:2021  |g month:01  |g elocationid:1758835921996509  |g pages:1-13  |g extent:13  |a Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer 
856 4 0 |u https://doi.org/10.1177/1758835921996509  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210612 
992 |a 20210612 
993 |a Article 
993 |a Article 
994 |a 2021 
994 |a 2021 
998 |g 138659702  |a Christopoulos, Petros  |m 138659702:Christopoulos, Petros  |d 50000  |d 910000  |d 950000  |d 950900  |e 50000PC138659702  |e 910000PC138659702  |e 950000PC138659702  |e 950900PC138659702  |k 0/50000/  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 19  |y j 
998 |g 1054438781  |a Thomas, Michael  |m 1054438781:Thomas, Michael  |d 50000  |d 910000  |d 950000  |d 950900  |e 50000PT1054438781  |e 910000PT1054438781  |e 950000PT1054438781  |e 950900PT1054438781  |k 0/50000/  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 18 
998 |g 139606106  |a Stenzinger, Albrecht  |m 139606106:Stenzinger, Albrecht  |d 910000  |d 912000  |e 910000PS139606106  |e 912000PS139606106  |k 0/910000/  |k 1/910000/912000/  |p 17 
998 |g 111184576  |a Bischoff, Helge  |m 111184576:Bischoff, Helge  |d 910000  |d 950000  |d 950900  |e 910000PB111184576  |e 950000PB111184576  |e 950900PB111184576  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 16 
998 |g 1020440112  |a Schirmacher, Peter  |m 1020440112:Schirmacher, Peter  |d 910000  |d 912000  |e 910000PS1020440112  |e 912000PS1020440112  |k 0/910000/  |k 1/910000/912000/  |p 15 
998 |g 103740324X  |a Kriegsmann, Mark  |m 103740324X:Kriegsmann, Mark  |d 910000  |d 912000  |d 50000  |e 910000PK103740324X  |e 912000PK103740324X  |e 50000PK103740324X  |k 0/910000/  |k 1/910000/912000/  |k 0/50000/  |p 14 
998 |g 133724484  |a Fischer, Jürgen  |m 133724484:Fischer, Jürgen  |d 50000  |e 50000PF133724484  |k 0/50000/  |p 12 
998 |g 110057378X  |a El-Shafie, Rami  |m 110057378X:El-Shafie, Rami  |d 910000  |d 911400  |e 910000PE110057378X  |e 911400PE110057378X  |k 0/910000/  |k 1/910000/911400/  |p 11 
998 |g 1056885432  |a Muley, Thomas  |m 1056885432:Muley, Thomas  |d 910000  |d 950000  |d 950900  |e 910000PM1056885432  |e 950000PM1056885432  |e 950900PM1056885432  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 10 
998 |g 1078792046  |a Meister, Michael  |m 1078792046:Meister, Michael  |d 910000  |d 950000  |d 950900  |e 910000PM1078792046  |e 950000PM1078792046  |e 950900PM1078792046  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 9 
998 |g 143005952  |a Eichhorn, Florian  |m 143005952:Eichhorn, Florian  |d 910000  |d 950000  |d 950900  |e 910000PE143005952  |e 950000PE143005952  |e 950900PE143005952  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 8 
998 |g 1048631389  |a Heußel, Claus Peter  |m 1048631389:Heußel, Claus Peter  |d 910000  |d 950000  |d 950900  |d 50000  |e 910000PH1048631389  |e 950000PH1048631389  |e 950900PH1048631389  |e 50000PH1048631389  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |k 0/50000/  |p 7 
998 |g 1016095236  |a Herth, Felix  |m 1016095236:Herth, Felix  |d 910000  |d 950000  |d 950900  |d 50000  |e 910000PH1016095236  |e 950000PH1016095236  |e 950900PH1016095236  |e 50000PH1016095236  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |k 0/50000/  |p 6 
998 |g 1017178976  |a Kirchner, Martina  |m 1017178976:Kirchner, Martina  |d 50000  |e 50000PK1017178976  |k 0/50000/  |p 5 
998 |g 114929650X  |a Kazdal, Daniel  |m 114929650X:Kazdal, Daniel  |d 910000  |d 912000  |e 910000PK114929650X  |e 912000PK114929650X  |k 0/910000/  |k 1/910000/912000/  |p 4 
998 |g 173874916  |a Volckmar, Anna-Lena  |m 173874916:Volckmar, Anna-Lena  |d 910000  |d 912000  |e 910000PV173874916  |e 912000PV173874916  |k 0/910000/  |k 1/910000/912000/  |p 3 
998 |g 141921811  |a Bozorgmehr, Farastuk  |m 141921811:Bozorgmehr, Farastuk  |d 910000  |d 950000  |d 950900  |e 910000PB141921811  |e 950000PB141921811  |e 950900PB141921811  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 2 
998 |g 1163245836  |a Magios, Nikolaus  |m 1163245836:Magios, Nikolaus  |d 910000  |d 950000  |d 950900  |e 910000PM1163245836  |e 950000PM1163245836  |e 950900PM1163245836  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 1  |x j 
999 |a KXP-PPN1760352888  |e 3937347402 
999 |a KXP-PPN1760352888  |e 3937347380 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Nikolaus Magios, Farastuk Bozorgmehr, Anna-Lena Volckmar, Daniel Kazdal, Martina Kirchner, Felix J. Herth, Claus-Peter Heussel, Florian Eichhorn, Michael Meister, Thomas Muley, Rami A. Elshafie, Jürgen R. Fischer, Martin Faehling, Mark Kriegsmann, Peter Schirmacher, Helge Bischoff, Albrecht Stenzinger, Michael Thomas and Petros Christopoulos"]},"id":{"doi":["10.1177/1758835921996509"],"eki":["1760352888"]},"origin":[{"dateIssuedDisp":"March 24, 2021","dateIssuedKey":"2021"}],"person":[{"given":"Nikolaus","role":"aut","family":"Magios","display":"Magios, Nikolaus"},{"given":"Farastuk","role":"aut","family":"Bozorgmehr","display":"Bozorgmehr, Farastuk"},{"given":"Anna-Lena","role":"aut","family":"Volckmar","display":"Volckmar, Anna-Lena"},{"display":"Kazdal, Daniel","role":"aut","given":"Daniel","family":"Kazdal"},{"display":"Kirchner, Martina","role":"aut","given":"Martina","family":"Kirchner"},{"role":"aut","given":"Felix","family":"Herth","display":"Herth, Felix"},{"given":"Claus Peter","role":"aut","family":"Heußel","display":"Heußel, Claus Peter"},{"display":"Eichhorn, Florian","given":"Florian","role":"aut","family":"Eichhorn"},{"display":"Meister, Michael","given":"Michael","role":"aut","family":"Meister"},{"given":"Thomas","role":"aut","family":"Muley","display":"Muley, Thomas"},{"role":"aut","given":"Rami","family":"El-Shafie","display":"El-Shafie, Rami"},{"display":"Fischer, Jürgen","role":"aut","given":"Jürgen","family":"Fischer"},{"display":"Faehling, Martin","role":"aut","given":"Martin","family":"Faehling"},{"display":"Kriegsmann, Mark","role":"aut","given":"Mark","family":"Kriegsmann"},{"display":"Schirmacher, Peter","family":"Schirmacher","given":"Peter","role":"aut"},{"display":"Bischoff, Helge","family":"Bischoff","given":"Helge","role":"aut"},{"display":"Stenzinger, Albrecht","family":"Stenzinger","role":"aut","given":"Albrecht"},{"display":"Thomas, Michael","role":"aut","given":"Michael","family":"Thomas"},{"display":"Christopoulos, Petros","role":"aut","given":"Petros","family":"Christopoulos"}],"relHost":[{"disp":"Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancerTherapeutic advances in medical oncology","physDesc":[{"extent":"Online-Ressource"}],"recId":"604082282","note":["Gesehen am 15.03.2012"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"text":"13(2021) vom: Jan., Artikel-ID 1758835921996509, Seite 1-13","volume":"13","extent":"13","pages":"1-13","year":"2021"},"title":[{"title_sort":"Therapeutic advances in medical oncology","title":"Therapeutic advances in medical oncology"}],"id":{"issn":["1758-8359"],"eki":["604082282"],"zdb":["2503443-1"]},"pubHistory":["1.2009 -"],"origin":[{"dateIssuedKey":"2009","publisherPlace":"Thousand Oaks, Calif.","dateIssuedDisp":"2009-","publisher":"Sage"}]}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"note":["Gesehen am 12.06.2021"],"title":[{"title_sort":"Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer","title":"Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer"}],"physDesc":[{"extent":"13 S."}],"recId":"1760352888"} 
SRT |a MAGIOSNIKOREALWORLDI2420